The European Medicines Agency Has Validated For Review The Marketing Authorization Application Of Genmab/Pfizer's Tisotumab Vedotin For Recurrent Or Metastatic Cervical Cancer With Disease Progression On Or After Systemic Therapy
Author: Benzinga Newsdesk | February 02, 2024 07:47am